HGF and hepatocellular carcinoma: Current drugs, such as dasatinib (XL228), which targets insulin-like growth factor (IGF) signaling, and benzoic acid derivative, which blocks hepatocyte growth factor (HGF) signaling, appear to reduce HCC metastases, but their critical molecular targets remain unclear [29,30].